Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review.
BACKGROUND
The proven efficacy of several anti-cholinergics and beta(2)-agonists and their combinations in both chronic obstructive pulmonary disease (COPD) and asthma strongly validates this therapeutic approach. As a consequence and although technically challenging, over the past 4 years there has been a growing interest in the generation of dual pharmacology Muscarinic-receptor antagonists-beta(2)-adrenergic receptor agonists (MABAs) for the treatment of COPD.


OBJECTIVE
This article surveys and reviews the research activity in the MABA area to the end of August 2008.


CONCLUSIONS
Although the activity in this field seems to still be limited to a few companies, significant progress in the discovery of a MABA has been achieved with the progression of at least one candidate (GSK-961081) to the clinic.
Argenta Discovery Ltd, 8-9 Spire Green Centre, Flex Meadow, Essex CM19 5TR, Harlow, UK. nick.ray@argentadiscovery.com
Nicholas C
NC
Ray
Lilian
L
Alcaraz
D000318:Adrenergic beta-Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001249:Asthma / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D018727:Muscarinic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D010330:Patents as Topic; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D018727:Muscarinic Antagonists